Premium
Antithrombotic phosphoinositide 3‐kinase β inhibitors in humans: a ‘shear’ delight!
Author(s) -
JACKSON S. P.,
SCHOENWAELDER S. M.
Publication year - 2012
Publication title -
journal of thrombosis and haemostasis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.947
H-Index - 178
eISSN - 1538-7836
pISSN - 1538-7933
DOI - 10.1111/j.1538-7836.2012.04912.x
Subject(s) - antithrombotic , platelet , phosphoinositide 3 kinase , kinase , platelet activation , medicine , chemistry , pi3k/akt/mtor pathway , biochemistry , signal transduction
Jackson SP, Schoenwaelder SM. Antithrombotic phosphoinositide 3‐kinase β inhibitors in humans: a ‘shear’ delight! J Thromb Haemost 2012; 10 : 2123–6. See also Nylander S, Kull B, Bjorkman JA, Ulvinge J‐C, Oakes N, Emanuelsson BM, Andersson M, Skarby T, Inghardt T, Fjellstrom O, Gustafsson D. Human target validation of phosphoinositide 3‐kinase (PI3K)β:effects on platelets and insulin sensitivity, using AZD6482 a novel PI3Kβ inhibitor. This issue, pp 2127–36.